Effective boards are not just collections of supporters. Founders should strategically recruit members with specific expertise they lack—such as legal, finance, or late-stage R&D. This creates a complementary team to navigate diverse challenges, provided everyone is fundamentally aligned with the company's ultimate vision.

In a tough funding market for companies without clinical data, Ikarovec's CEO notes that investors heavily weigh the team's credibility. The combination of his own experience with FDA approvals, a seasoned CSO, and a board with multiple billion-dollar exits is a key factor that resonates with investors.

When capitalizing your business, select investors for their experience, not just their money. Prioritize people who have a history of successful exits. They provide a proven playbook you can model your business against and, as partners on your cap table, their strategic influence is critical to your journey.

When fundraising, the most critical choice isn't the VC fund's brand but the specific partner who will join the board. Sophisticated founders vet the individual's strengths, weaknesses, and working style, as that person has a more direct impact on the company than the firm's logo on a term sheet.

Founders with deep scientific backgrounds often make a critical error: they become tunnel-visioned on the next scientific experiments. When approaching investors, they spend too little time planning how to assemble a team to fill their own skill gaps and how to create a viable business and revenue model.

Jeni Britton advises a founder to build a board of advisors even before raising significant capital. This practice provides valuable guidance, forces organizational discipline, and signals to future investors that the company is professionally managed, giving the founder more leverage in negotiations.

To attract investment, founders must translate their science into a business case. This involves articulating the target customer, go-to-market strategy, cost structure, and value proposition. Investors back ventures that connect three key elements: strong science, a clear clinical need, and a credible business model.

To attract quality investment, a biotech must present a complete package. A great scientific idea alone is insufficient. It requires initial supporting data to validate the concept and a talented execution-focused team to transform that data into a clinical asset. All three are essential.

A primary strategy for early-stage investment is partnering with entrepreneurs with a successful track record, often from previous portfolio companies. VCs will back a person they trust, like a former Chief Scientific Officer or a repeat founder, valuing proven execution experience sometimes even more than a nascent scientific concept.